Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia
Cytometry Part B: Clinical Cytometry · 2024
DOI: 10.1002/cyto.b.22153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2024. Verfasst von Emilia Boris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Hematology, St Eloi Hospital, Montpellier University Hospital, Montpellier, France. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National du Cancer (INCA), SIRIC Montpellier Cancer, ARC foundation PGA EpiMM3D, Institut Carnot CALYM, Labex EpiGenMed, FFRMG.
Abstract (Originalsprache)
Background
Multiparametric flow cytometry (MFC) is an essential diagnostic tool in B acute lymphoblastic leukemia (B ALL) to determine the B‐lineage affiliation of the blast population and to define their complete immunophenotypic profile. Most MFC strategies used in routine laboratories include leukemia‐associated phenotype (LAP) markers, whose expression profiles can be difficult to interpret. The aim of our study was to reach a better understanding of 7 LAP markers' landscape in B ALL: CD9, CD21, CD66c, CD58, CD81, CD123, and NG2.
Methods
Using a 10‐color MFC approach, we evaluated the level of expression of 7 LAP markers including CD9, CD21, CD66c, CD58, CD81, CD123, and NG2, at the surface of normal peripheral blood leukocytes ( n = 10 healthy donors), of normal precursor B regenerative cells ( n = 40 uninvolved bone marrow samples) and of lymphoblasts ( n = 100 peripheral blood samples or bone marrow samples from B ALL patients at diagnosis). The expression profile of B lymphoblasts was analyzed according the presence or absence of recurrent cytogenetic aberrations. The prognostic value of the 7 LAP markers was examined using Maxstat R algorithm.
Results
In order to help the interpretation of the MFC data in routine laboratories, we first determined internal positive and negative populations among normal leukocytes for each of the seven evaluated LAP markers. Second, their profile of expression was evaluated in normal B cell differentiation in comparison with B lymphoblasts to establish a synopsis of their expression in normal hematogones. We then evaluated the frequency of expression of these LAP markers at the surface of B lymphoblasts at diagnosis of B ALL. CD9 was expressed in 60% of the cases, CD21 in only 3% of the cases, CD58 in 96% of the cases, CD66c in 45% of the cases, CD81 in 97% of the cases, CD123 in 72% of the cases, and NG2 in only 2% of the cases. We confirmed the interest of the CD81/CD58 MFI expression ratio as a way to discriminate hematogones from lymphoblasts. We observed a significant lower expression of CD9 and of CD81 at the surface of B lymphoblasts with a t(9;22)( BCR‐ABL ) in comparison with B lymphoblasts without any recurrent cytogenetic alteration ( p = 0.0317 and p = 0.0011, respectively) and with B lymphoblasts harboring other cytogenetic recurrent abnormalities ( p = 0.0032 and p < 0.0001, respectively). B lymphoblasts with t(1;19) at diagnosis significantly overexpressed CD81 when compared with B lymphoblasts with other recurrent cytogenetic abnormalities or without any recurrent alteration ( p = 0.0001). An overexpression of CD58 was also observed in the cases harboring this abnormal cytogenetic event, when compared with B lymphoblasts with other recurrent cytogenetic abnormalities ( p = 0.030), or without any recurrent alteration ( p = 0.0002). In addition, a high expression of CD123, of CD58 and of CD81 was associated with a favorable prognosis in our cohort of pediatric and young adult B ALL patients. We finally built a risk score based on the expression of these 3 LAP markers, this scoring approach being able to split these patients into a high‐risk group (17%) and a better outcome group (83%, p < 0.0001).
Conclusion
The complexity of the phenotypic signature of lymphoblasts at diagnosis of B ALL is illustrated by the variability in the expression of LAP antigens. Knowledge of the expression levels of these markers in normal leukocytes and during normal B differentiation is crucial for an optimal interpretation of diagnostic cytometry results and serves as a basis for the biological follow‐up of B ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Hematology, St Eloi Hospital, Montpellier University Hospital, Montpellier, France.
- Department of Pediatric Onco-Hematology, Arnaud de Villeneuve Hospital, Montpellier University Hospital, Montpellier, France.
- Faculty of Medicine, University of Montpellier, Montpellier, France.
- Laboratory of Medical Biology, Beziers Hospital, France.
- CNRS UMR 9002, Institute of Human Genetics, Montpellier, France.
- Institut Universitaire de France, Paris, France.
ORCID-Profile: Alexandre Theron, Jérôme Moreaux, Caroline Bret
Förderung
- Institut National du Cancer (INCA)
- SIRIC Montpellier Cancer
- ARC foundation PGA EpiMM3D, Institut Carnot CALYM, Labex EpiGenMed, FFRMG
- HORIZON-MISS-2021-CANCER-02-European research project ELMUMY, INSERM PSCI 2020 Smooth-MM, MUSE LabUM Epigenmed, AAP READYNOV
- Institut Universitaire de France
Zitieren
APA
Boris, E., Theron, A., Montagnon, V., Rouquier, N., Almeras, M., Moreaux, J., & Bret, C. (2024). Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22153
Vancouver
Boris E, Theron A, Montagnon V, Rouquier N, Almeras M, Moreaux J, et al. Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia. Cytometry Part B: Clinical Cytometry. 2024. doi:10.1002/cyto.b.22153
BibTeX
@article{Boris2024,
author = {Boris, Emilia and Theron, Alexandre and Montagnon, Valentin and Rouquier, Nicolas and Almeras, Marion and Moreaux, Jérôme and Bret, Caroline},
title = {Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2024},
doi = {10.1002/cyto.b.22153}
}
EUVIMED